CCT-018159

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H20N2O4
Molecular Weight	352.3838
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C(O)C=C(O)C(=C1)C2=NNC(C)=C2C3=CC=C4OCCOC4=C3

InChI

InChIKey=OWPMENVYXDJDOW-UHFFFAOYSA-N

InChI=1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C20H20N2O4
Molecular Weight	352.3838
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17431102 | https://www.ncbi.nlm.nih.gov/pubmed/17332351 | https://www.ncbi.nlm.nih.gov/pubmed/16818523

CCT-018159 is a novel inhibitor of heat shock protein (Hsp) 90 with potential anticancer activity. CCT-018159 inhibited human HSP90beta with comparable potency to 17-AAG and with similar ATP-competitive kinetics. The mean cellular GI(50) value of CCT-018159 across a panel of human cancer cell lines, including melanoma, was 5.3 mumol/L. CCT-018159 caused cell cytostasis associated with a G(1) arrest and induced apoptosis. CCT-018159 also inhibited key endothelial and tumor cell functions implicated in invasion and angiogenesis. CCT-018159 has the potential to inhibit invasion and angiogenesis as part of combinatorial anticancer effects. CCT-018159 is still in the preclinical development stage for the treatment of cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Heat shock protein HSP 90-beta 13 Target ID: CHEMBL4303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17332351 \| https://www.ncbi.nlm.nih.gov/pubmed/15955698	Inhibitor 8297		3.2 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: http://adisinsight.springer.com/drugs/800018517 https://www.ncbi.nlm.nih.gov/pubmed/25579569	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Potential role of Hsp90 in rat islet function under the condition of high glucose.	2016 Aug	26997509

Patents

Sample Use Guides

In Vivo Use Guide

Mice: CCT-018159 was administered i.v. and p.o., at 20 mg/kg or in combination with other heat shock protein 90 inhibitors at 4 mg/kg each.

Route of Administration: Other

In Vitro Use Guide

The IC50 value for CCT-018159 against the ATPase activity of full-length yeast Hsp90 at 400 umol/L ATP was 6.6 +/- 0.5 umol/L. At 10 and 100 umol/L CCT-018159, no inhibition was observed against human HSP72. ATPase or the decatenation activity of human topoisomerase II. In a panel of 20 representative kinases, CCT-018159 at 50 umol/L showed <50% inhibition in 13 of these kinases. The mean cellular GI(50) value of CCT-018159 across a panel of human cancer cell lines, including melanoma, was 5.3 umol/L.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:30:47 GMT 2023` Edited by `admin` on `Sat Dec 16 10:30:47 GMT 2023`
Record UNII	55H1ZOI1NL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CCT-018159

Common Name

English

1,3-BENZENEDIOL, 4-(4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-5-METHYL-1H-PYRAZOL-3-YL)-6-ETHYL-

Systematic Name

English

Code System Code Type Description

FDA UNII

55H1ZOI1NL